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evaluating a strategy of primary surgery and
adjuvant chemotherapy versus peri-operative
chemotherapy for resectable gastric signet ring
cell adenocarcinomas – PRODIGE 19 – FFCD1103 –
ADCI002
Guillaume Piessen1,2,3*, Mathieu Messager1,2,3, Karine Le Malicot4, William B Robb1,2, Frédéric Di Fiore5,
Marie Guilbert1,2, Marie Moreau4, Véronique Christophe6, Antoine Adenis7 and Christophe Mariette1,2,3Abstract
Background: A dramatic increase in the incidence of the diffuse form of gastric adenocarcinomas and particularly
signet ring cell carcinomas has been observed in Western countries. Evidence is accruing that signet ring cell
carcinomas may have inherent chemo resistance leaving many clinicians unsure of the benefits of delaying surgery
to pursue a neoadjuvant approach.
Methods/design: PRODIGE-19-FFCD1103-ADCI002 is a prospective multicentre controlled randomised phase II/III
trial comparing current standard of care of perioperative chemotherapy (2x3 cycles of Epirubicin, cisplatin, 5-fluorouracil)
with a strategy of primary surgery followed by adjuvant chemotherapy (6 cycles of Epirubicin, cisplatin, 5-fluorouracil) in
patients with a stage IB-III gastric signet ring cell tumour. The principal objective of the phase II study (84 patients) is to
determine if the experimental arm (primary surgery followed by adjuvant chemotherapy) has sufficient interest in terms
of percentage of living patients at 24 months to be evaluated in a phase III trial. If 7 or less patients in the experimental
arm are alive at 24 months, phase III will not be initiated. The primary objective of phase III (230 additional patients) is to
demonstrate superiority of the experimental arm in terms of overall survival. Secondary endpoints include overall
survival at 36 months, disease free survival at 24 and 36 months, R0 resection rates, treatment tolerance, postoperative
mortality and morbidity evaluated by Clavien-Dindo severity index, the prognostic impact of positive peritoneal
cytology and the assessment of quality of life. An ancillary study will assess the emotional and cognitive impact of
surgery and perioperative chemotherapy for both the patient and their partner.
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Discussion: As inherent chemo resistance of signet ring cell tumours and delay in definitive surgery may favour
tumour progression we hypothesise that a policy of primary surgery followed by adjuvant chemotherapy will improve
overall survival compared to a standard perioperative chemotherapeutic strategy. This randomised phase II/III trial is the
first dedicated to this histological subtype. Whilst the development of new biomarkers and targeted therapies are
awaited, the results of this trial should further help in devising individualised protocols of patient care in a tumour
group whose diversity increasingly demands assessment of alternative strategies.
Trial registration: ClinicalTrials.gov, NCT01717924
Keywords: Signet ring cells, Gastric adenocarcinoma, Surgery, Perioperative chemotherapy, Randomized study,
Emotion, CoupleBackground
Gastric adenocarcinoma (GA), despite its decreasing
overall incidence, still remains the 5th most frequently di-
agnosed cancer and the second most common cause of
cancer related death worldwide [1,2]. It is a heterogeneous
disease with two histological classifications mainly being
used. The Lauren classification [3] primarily differentiates
between “intestinal” and “diffuse” types. The intestinal
type corresponds to tubular or villous well-differentiated
GA whereas the diffuse type corresponds to less differenti-
ated and more infiltrative GA and includes signet ring cell
adenocarcinomas (SRCs). As GA is typically a mixture of
histological patterns, the World Health Organisation clas-
sification [4] has defined SRCs as an adenocarcinoma in
which the predominant component (more than 50% of
the tumour) consists of isolated or small groups of malig-
nant cells containing intracytoplasmic mucins. A dramatic
increase in the incidence of the diffuse form of gastric
cancer and particularly SRCs has been observed, mainly in
Western [5,6]. Consequently, in the most recent western
studies, SRCs represents 16% to 45.4% of GAs [5,7,8].
The phase III trials [9,10] which have established peri-
operative chemotherapy as the European standard of
treatment for gastric cancers provide no subgroup analysis
of the efficacy of this strategy for SRC tumours. A few
retrospective [11-13] and prospective publications [14],
with limited numbers of patients, have however suggested
SRCs may have inherent chemo resistance. These observa-
tions have left many clinicians unsure of the benefits of
delaying definitive surgery and pursuing a neoadjuvant ap-
proach for a tumour which behaves aggressively and dis-
plays significant resistance to current chemotherapy.
To support these observations and establish more reli-
able data regarding the behaviour of SRC tumours, at
the start of 2010 our team launched a French retrospect-
ive multicenter study of all consecutive oesophagogastric
adenocarcinomas in 19 centres in France treated be-
tween January 1997 and January 2010 (ADCI001) [8].
Amongst 3010 patients registered 1050 (34.9%) had a
SRC tumour, with 126 being metastatic at diagnosis and
excluded from the study. The remaining 924 patientsunderwent an intention to treat analysis according to
whether they underwent primary surgery (n = 753,
81.5%) or neoadjuvant chemotherapy (n = 171, 18.5%).
Multivariate analysis showed pre-operative chemotherapy
to be an independent predictor of poor survival (HR = 1.4,
95% CI 1.1-1.9, p = 0.042), with overall survival at 2 years
of 27.1% in the primary surgery group versus 12.3% in pa-
tients treated with neoadjuvant chemotherapy. Hence, in-
creasingly data is suggestive of SRC chemo resistance, and
a deleterious effect of delaying definitive surgery for an in-
effective treatment whose toxicity may cause host im-
munosuppression facilitating disease progression.
There is therefore clear impetus for a prospective
randomised study to evaluate the appropriate periopera-
tive therapeutic strategy for SRCs.Methods/design
Protocol overview
PRODIGE-19-FFCD1103-ADCI002 is a prospective multi-
centre controlled randomised phase II/III trial comparing
current standard of care (2x3 cycles of perioperative
Epirubicin, cisplatin, 5-fluorouracil (ECF) chemotherapy)
with a strategy of primary surgery followed by adjuvant
ECF chemotherapy (6 cycles) in patients with a SRC
tumour and eligible for curative surgery. In phase II pa-
tients will be randomised using minimisation with stratifi-
cation criteria – centre, tumour stage, performance status
and tumour localisation. The principal objective will be to
determine if the experimental arm (primary surgery
followed by adjuvant chemotherapy) has a sufficient inter-
est in terms of percentage of living patients at 24 months
to be evaluated in a phase III trial. If ≤10% of patients in
the experimental arm is alive at 24 months, phase III will
not be initiated. Recruitment will be postponed for a 6
month period after the completion of phase II of the study
to allow for the interim analysis of data. The primary ob-
jective of phase III will be to demonstrate the superiority
of the experimental arm in terms of overall survival. The
study is planned for a total duration of 10 years and is reg-
istered on clinicaltrial.gov website (NCT01717924).
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PRODIGE-19 will include patients with an adenocarcin-
oma of the stomach and Siewert type III tumours of the
oesophago-gastric junction, with histological proof on
pre-therapeutic biopsies of either a SRC tumour or dif-
fuse type tumour according to the Lauren classification.
Reliability of samples obtained from routine pre-
treatment endoscopic biopsies to predict SRC histology
has been recently demonstrated by our group [15].
All tumours of stage IB to III will be included (T1N+,
T2N0 N+, T3N0 N+, T4N0 N+) as staged by routine
endoscopic ultrasound examination (EUS), or by comput-
erised tomography if the tumour is non-traversable at
EUS. Patients will be between the ages of 18 and 80, must
be assessed as suitable for curative surgery with the ab-
sence of visceral metastases or evidence of peritoneal car-
cinomatosis during a mandatory pretherapeutic staging
laparoscopy. All included patients must have a weight loss
of less ≤15% of body mass, have a World Health Organisa-
tion performance status of ≤2, with an ejection fraction of
≥50% prior to the administration of Epirubicin and must
not have been previously treated with either chemotherapy
or radiotherapy for a gastric cancer. Patients must have
a neutrophil count of ≥1500/mm3, platelet count of
≥100,000/mm3, a creatinine clearance of >50ml/minute
and a total Bilirubin <1.5 times the upper limit of normal.
All patients must give their informed consent for partici-
pation in this trial.
Exclusion criteria
All patients who do not meet the inclusion criteria will
be excluded. Other contraindications to participation in-
clude tumours classified as T1N0 by preoperative sta-
ging, the presence of other malignant tumours treated
with curative intent within 5 years (with the exception of
basal cell carcinoma of the skin and carcinoma in situ of
the cervix), patients previously treated with abdominal
or thoracic radiation and patients with a known allergy
to one of the trial medications. Current pregnancy or
breastfeeding will render females ineligible. Evolving car-
diac, renal and respiratory insufficiency, as well as myocar-
dial infarction within 6 months and known Child’s B or C
cirrhosis will all also warrant patient exclusion. Finally pa-
tients who are not capable for family, social, psychological
or geographical reasons to attend for regular follow-up
and who do not have legal capacity will not be included.
Endpoints of trial
The primary endpoint of this trial will be the evaluation
of the percentage of patients still alive 24 months after
randomisation. The secondary endpoints for this trial in-
clude, overall survival (OS) at 36 months, disease free
survival (DFS) at 24 and 36 months, R0 resection rates,
treatment tolerance, postoperative mortality and morbidityevaluated by Clavien-Dindo severity index [16], rates of
completion of all elements of the planned therapy, the
prognostic impact of positive peritoneal cytology and the
assessment of quality of life (EORTC QLC-C30 and
EORTC STO 22). A complementary study, subsequently
described, will assess the emotional and cognitive impact
of surgery and perioperative chemotherapy for both the
patient and their partner.
OS is defined as the time interval between inclusion
and death from whatever cause and patients lost to
follow-up will be censured at the last date of follow-up.
Disease free survival will be defined as the time interval
between the date of inclusion and the date of first recur-
rence or the date of death in the absence of disease re-
currence. The R0 resection rate will correspond to the
percentage of patients benefitting from a micro and
macroscopically complete resection [17]. Neoadjuvant
and/or adjuvant treatment tolerance will be estimated
according to the National Cancer Institute Toxicity Cri-
teria (NCI-CTC version 4.0). Evaluation of the uptake of
all elements of planned treatment will be performed and
quality of life questionnaires and human and social sci-
ences questionnaires will be completed at 4 defined time-
points – randomisation, the eve of commencement of
treatment, 1 month (+/−7 days) after leaving hospital fol-
lowing surgery and 1 month (+/−7 days) after completing
adjuvant chemotherapy. The quality of life questionnaires
will also be completed at each 4 monthly follow-up visit.
Randomisation
Randomisation will be performed by minimisation with
stratification criteria – centre, tumour stage, performance
status and tumour localisation. The maximum delay be-
tween randomisation and either the start of neoadjuvant
treatment or surgery will be 4 weeks. A randomisation
number and the treatment allocation are sent by facsimile
communication by the “Centre de Randomisation-Gestion-
Analyse” (CRGA) at the Fédération Francophone de
Cancérologie Digestive (FFCD) headquarters in Dijon,
France to the investigator after the receipt of the inclusion
form.
Pre-therapeutic work-up
Prior to inclusion in the trial an information booklet will
be given to each patient and the trial protocol will be
clearly explained. The initial work-up must take place in
the 4 weeks preceding randomisation and will comprise
of the following:
i) A complete physical examination.
ii) Estimation of full blood count, calculation of
creatinine clearance using the Cockcroft formula,
measurements of electrolytes, total protein, albumin,
alkaline phosphatase, aspartate transaminase,
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gamma-GT, pregnancy test for females of
reproductive years and discussion of contraceptive
methods during the trial period.
iii)Tumour markers evaluation – carcinoembryonic
antigen and carbohydrate antigen 19.9.
iv)Assessment of operability – electrocardiogram,
cardiac echography, anaesthetic consultation and
posterior-anterior and lateral chest x-ray (not
necessary where a CT thorax has been performed).
v) Oesophago-gastro-duodenoscopy with multiple
biopsies and examination by retroflexion.
vi) Contrast study.
vii) Contrast enhanced computerised tomography of
the thorax, abdomen and pelvis.
viii) Endoscopic ultrasound will be performed
systematically. The pre-therapeutic TNM
classification will be made by EUS, except for
tumours which cannot be traversed by EUS, in
which case the TNM stage will be based on CT
findings.
ix) Staging laparoscopy will be performed
systematically. All suspicious lesions will be biopsied
and a laparoscopic feeding jejunostomy will be
performed for patients who have lost >10% of
habitual body mass. Peritoneal fluid, if already
present, will be sampled prior to any manipulation
of the tumour and if the sample gives <50 mls,
100mls of normal saline will be instilled around the
primary tumour and 50mls recuperated from thePre-inclusion
4 weeks maximum
Inclusion  
Randomisation
Start of 
neoadjuvant 
chemotherapy
Reevalu
6-12 weeks
3-6
Surgery
Start of adjuvant
chemotherapy
< 4 weeks
Arm A
Arm B
2-3 we
Figure 1 Therapeutic scheme for the protocol.epigastric/left hypochondriac regions after a delay of
2 minutes without tumour manipulation. In cases of
the discovery of peritoneal carcinomatosis,
peritoneal cytology will not be performed.
x) Positron emission tomography scanning will not be
routinely performed due to the known weak tracer
uptake specific to SRC tumours [14].
Treatment methods
The therapeutic scheme for this trial is depicted in
Figure 1.
Chemotherapy regimens
Peri-operative chemotherapy (group A)
Patients randomised to group A will receive the
established European standard of treatment– 3 pre- and
postoperative cycles of ECF. Neoadjuvant treatment will
commence within 4 weeks of randomisation and each
cycle will last 21 days. Epirubicin will be administered
at a dose of 50 mg/m2 by intravenous infusion over 30
minutes on day 1 followed by intravenous infusion over
60 minutes of cisplatin at a dose of 60 mg/m2 and then
continuous infusion of 5-fluorouracil from days 1–21 at
a dose of 200 mg/m2/day. It will be permitted to replace
infusion of 5-fluorouracil with its oral equivalent
(capecitabine) depending on the normal treatment habits
of each centre.
Patients will undergo clinical and staging re-evaluation
2–3 weeks after completion of the neoadjuvant regimen
and surgical resection will be performed 3–6 weeks afteration
6-12 weeks weeks
Surgery Start of adjuvant 
chemotherapy
Chemotherapy : Epirubicin, 
Cisplatin,
5-Fluororuracil or Xeloda (ECF or 
ECX)
eks
Follow-up 4 monthly for 3 years
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chemotherapy will commence 6–12 weeks after surgery
and will comprise the same regimen where there has not
been disease progression or severe toxicity during the
neoadjuvant phase. If either of these events has occurred
the administration of the adjuvant chemotherapy or the
protocol for its substitution will be left to the decision of
the local multi-disciplinary team meeting. Clinical,
haematological and toxicity evaluations will be carried
out prior to administration of each cycle of chemother-
apy and an echocardiogram will be performed prior to
neoadjuvant and adjuvant treatments and at the conclu-
sion of adjuvant treatment.
Adjuvant chemotherapy regimen - group B
Patients randomised to group B will undergo primary
surgery followed by 6 cycles of adjuvant ECF chemo-
therapy. Primary surgical resection will take place within
4 weeks of randomisation. Six cycles of adjuvant chemo-
therapy will commence 6–12 weeks after surgical resec-
tion. Each cycle of chemotherapy will consist of the
same regimen of ECF as used for group A and at the
same dosage.
Re-staging post neoadjuvant chemotherapy (group A)
Tumoural restaging will be performed 2–3 weeks after
the end of neoadjuvant chemotherapy. It will comprise
of the following examinations; clinical examination,
same blood analyses as at inclusion [see Pre-Therapeutic
Work-Up (ii)], tumour marker estimation (CEA and
CA19.9), anaesthetic consultation, oesophago-gastro-
duodenoscopy with multiple biopsies and retrovision,
radiological contrast study, CT thorax, abdomen and
pelvis and EUS evaluation. This re-evaluation will be
performed by the same team and by the same technique
as the initial work-up.
Surgical Resection
All surgical resections will be performed by open lapar-
otomy. At the start of definitive surgical resection, peri-
toneal cytology will be performed in order to study the
effects of, (a) preoperative chemotherapy on the results
of cytology performed during staging laparoscopy in
group A and, (b) the effect on peritoneal cytology of the
interval between exploratory laparoscopy and definitive
resection in group B.
Surgical resection will follow the French national
guidelines for GA, published by the SFCD-ACHBT
-HAS-INCA [18]. In view of the infiltrative nature of
SRC tumours, a total gastrectomy is recommended irre-
spective of the gastric tumour location. Nevertheless, for
small distal tumours, a partial gastrectomy may be con-
sidered on a case by case basis whilst safeguarding the
usual oncological principles of resection. For Siewerttype III tumours of the gastro-oesophageal junction the
recommendations for resection will apply apart from the
requirement of an 8 cm proximal tumour free resection
margin. When resection is extended to the lower
oesophagus, either transhiatally or via thoracotomy, the
lower oesophagus will be resected en bloc with a lower
mediastinal lymphadenectomy. Frozen section analysis
of the proximal and distal resection margins will be rou-
tinely performed. An enlarged resection to adjacent or-
gans will be performed when necessary to obtain an R0
resection and, when noted, resection of peri-tumoural
localised carcinomatosis will also be performed. A D2
lymphadenectomy without distal pancreatectomy and
splenectomy will be standard, with the harvest of at least
25 lymph nodes. In both treatment arms the trial proto-
col recommends the placement of a feeding jejunostomy
to limit post-operative weight loss and to help facilitate
tolerance of subsequent adjuvant therapy.
Standards of peri-operative care
Patients will be required to abstain from smoking and al-
cohol for 1 month pre-operatively. Supplemental enteral
nutrition will be given to patients who have lost >10% of
their baseline body mass and all patients will receive
7 days of pre-operative immunonutrition by Oral Impact®
independent of their nutritional status [19].
All patients will receive appropriate antibiotic prophy-
laxis at induction of anaesthesia and post-operative anal-
gesia will be by patient controlled epidural analgesia
(PCEA) or alternatively by standard patient controlled
analgesia (PCA). Post-operative nutrition will be com-
menced on day 2 or 3 post-operation via the jeju-
nostomy and at an initial low volume (250 mls) and
increased incrementally. Deep vein prophylaxis will be
administered routinely by low molecular weight heparin.
Chest physiotherapy and post-operative incentive spir-
ometry will be standard for all patients. In cases where
an anastomotic leak is suspected the investigation of ref-
erence will be an upper gastro-intestinal endoscopy, or
alternatively a CT scan with both injection and ingestion
of contrast medium.
Histological analysis
Pathological examination of the operative specimen
must report upon: tumour location, type of operation,
details of lymphadenectomy and detailed description or
lymph node stations, a macroscopic tumour description,
definitive histological classification, documentation of
the % of signet ring type cells, Lauren classification, de-
finitive results of per-operative frozen sections, pTNM/
ypTNM stage according to the 2009 7th edition of the
UICC classification for gastric cancers, resection
radicality (R0, R1, R2) and documentation of histological
tumour response after neoadjuvant chemotherapy.
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Participating patients will be reviewed in out-patients 1
month (+/−7 days) after hospital discharge. They will
have a full clinical examination. Questionnaires will be
completed with regards to quality of life (QoL), emo-
tional state, emotional adjustment, perception of illness
and lifestyle burden. A further consultation will be
scheduled for one month (+/−7days) after completion of
adjuvant chemotherapy with evaluation of clinical state,
treatment tolerance, haematological parameters, renal
function, tumour markers, evaluation of cardiac ejection
fraction after Epirubicin by echocardiogram and the
same set of questionnaires will be completed.
All participants will subsequently be followed for 3
years after randomisation. Out-patient consultations will
be scheduled every 4 months (+/−15 days) and patients
will be evaluated by clinical examination, thoraco-
abdominal CT scan, tumour marker estimation (CEA
and CA19.9) and QoL questionnaires. Further examina-
tions will be requested as required. If disease recurrence
is suspected its site (loco regional or distant) must be
documented by the appropriate investigations and histo-
logical proof be obtained wherever possible. In cases of
strong clinical suspicion of recurrence without radio-
logical or histological proof, surgical exploration is
recommended to identify peritoneal carcinomatosis not
visualised by standard radiological investigation. All
cases of disease recurrence will be discussed at the
multi-disciplinary team meeting and further therapeutic
strategies recorded.
Reasons for discontinuing treatment protocol
The treatment protocol may be discontinued for the fol-
lowing reasons: decision of the treating doctor, high
grade toxicity, occurrence of a serious adverse effect, dis-
ease progression, patient refusal to continue and patient
death. In cases where treatment is discontinued, patients
will remain within the intention to treat analysis.
Statistical evaluation and sample size calculation
Phase II– The phase II part of this trial will determine
the percentage of patients in the experimental limb of
the study (group B) who are alive at 24 months and thus
validate the interest pursuing the evaluation of a strategy
of primary surgery in a subsequent phase III trial. To
demonstrate the interest of the experimental arm of this
study, it will be necessary to include 40 in each treat-
ment arm, with a unilateral alpha error of 5% and a
power of 85%. Taking into account a 5% level of loss to
follow-up, 84 patients will be included in total (42 in
each treatment arm). If 7 or less patients are alive after
24 months, then the treatment B will be considered not
interesting. Survival data for patients from phase II of
this trial will allow for the readjustment of the numberof patients required to be enrolled in the phase III trial
according to the adaptive trial design.
Phase III – The objective of the phase III trial will
be to demonstrate the superiority of group B and the
principal outcome criteria will be overall survival. To
demonstrate a desired 10% difference in overall sur-
vival in favour of group B at 24 months, with a bilat-
eral alpha error of 5% and a power of 85%, it will be
necessary to observe 291 deaths. With an estimated
rate of inclusion of 6 patients per month, with a 5%
rate of loss to follow-up and surveillance of the last
included patient of 24 months, a total of 314 patients
will have to be recruited. On this basis 230 additional
patients will need to be recruited after the completion
of phase II.
Two intermediate analyses are planned, one for Phase
III sample size read justement and the second one to
allow for the early identification of the superiority of
group B. The first intermediate analysis of survival data
will take place at the end of phase II. The second inter-
mediate analysis will be performed after either 175
deaths or 60% of events have occurred.
Statistical analysis for phase II will be performed on a
modified intention to treat population meaning all pa-
tients who can be evaluated and who are not lost to fol-
low up at 24 months. For phase III, analysis of the main
criteria will be performed on an intention to treat (ITT)
principle. The per-protocol population will be defined as
the ITT population having no major deviation or major
of the protocol.
Continuous variables will be described by their mean
and standard deviation or median, Interquartile Interval
(Q1-Q3) and range. Survival endpoints will be estimated
using the Kaplan Meier method, described by median
values with 95% confidence Interval and compared in
Phase III using the log-rank test. QoL data will be
analysed according to treatment arm and treatment tol-
erance assessed using the National Cancer Institute Tox-
icity Criteria – (NCI CTC). The Clavien-Dindo scale will
be used to assess peri-operative complications [16]. Cox
univariate and multivariate analyses will allow explora-
tory analyses of prognostic factors, time until deterior-
ation of QoL and disease free survival.
Scheme for trial analysis (Figure 2)
Ancillary study
An ancillary study of Human and Social Sciences will be
performed entitled “Emotional and Cognitive Impact of
Surgery and Peri-Operative Chemotherapy on Patients
and Partners Diagnosed With a Gastric Adenocarcin-
oma”. The principal aim of this novel exploratory study
is the longitudinal assessment of the emotional and cog-
nitive state of the patient and partner according to allo-
cated treatment arm. Evaluation will be by the following
Final Analysis of Phase II: 
Assessment of whether 
Phase III is justified
First Intermediate analysis: 
Adaptation of Phase III by 
function of results from Phase II
2nd Intermediate Analysis:  
Early test for difference in 
overall survival
Test for futility of comparison 
and trial discontinuation if 
comparison shown to be futile.
Final 
Analysis
Phase II
175 deaths (60% 
events)
Phase II completed after 
84 patients included with  
24 months follow -up
Phase III
Start of 
Inclusions
291 deaths 
(100% events)
Figure 2 Scheme for trial analysis.
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QLQ-STO-22 for the patient and SF-36 for partner, Emo-
tional State – depression - CES-D and anxiety – STAI-Y-A
for patient and partner, Emotional Adjustment – WCC for
patient and partner, Perception of Disease – Brief-IPQ for
patient and partner, Comprehension of Trial – ICEC-R
for patient and partner, and Burden Assessment – CRA
for patient and partner). Assessment will take place at 4
measured time-points – randomisation, day prior to sur-
gery, prior to adjuvant treatment and on stopping adju-
vant treatment. This study will allow to know better
which therapeutic strategy, among the 3 compared, is the
best for the patient’s and their partner’s quality of life and
emotional state, which is determining in therapeutic deci-
sions and compliance to treatments, what coping strat-
egies promote the patient’s and their partner’s quality of
life and emotional state the best. This result will be par-
ticularly interesting to improve the psycho-oncological
care of the patient-partner couple: what perceptions the
patient and their partner have about the disease and clin-
ical trials, which are determining factors in therapeutic
compliance, and that need to be known to improve
psycho-oncological support in particular.
Ethical considerations
The study protocol was approved by the Institutional
Review Board, the Nord Ouest IV ethics committee on
the 15 of May 2012 and the Agence Nationale de
sécurité des médicaments et des produits de santé
(ANSM) on the 26 of June 2012 under the number
2012-000998-24. The institutional promoter is the Uni-
versity Hospital of Lille, France. The trial has been regis-
tered on the ClinicalTrial.gov website under the
identification number NCT01717924. This study has re-
ceived grant funding from the French National Cancer
Institute (INCA) in 2011. The study complies with the
Declaration of Helsinki rules and the principles ofGood Clinical Practice guidelines. Informed consent
will be obtained from each patient in written form
prior to randomisation and an information leaflet will
be given to each patient prior to inclusion in the
study. Patient safety and all potential threats to patient
safety will be monitored by an independent monitoring
board which will be able, taking into account undesirable
events and the level of post-operative mortality, rec-
ommend the discontinuation of one of the treatments
evaluated.
Discussion
Despite considerable advances in treatment, gastric can-
cer remains a disease with a poor prognosis. The hetero-
geneity of this disease, the distinct histological subtypes
and the intrinsic molecular diversity represent a chal-
lenge and an opportunity in developing individually tai-
lored therapy. The incidence of diffuse type GA,
particularly SRC type has been increasing and SRCs rep-
resents 16% to 45.4% of GA in recent Western studies
[5,7,8]. Tumours of SRC histology have several charac-
teristics which differentiate them from other tumour
types. They appear to affect patients at an earlier age
[12,20], typically present with a more advanced tumour
stage at diagnosis and carry a worse prognosis [12].
The advantage of perioperative treatment strategies for
gastric cancer has been demonstrated in several phase
III randomised controlled trials. The MAGIC study [9]
conducted in the United Kingdom tested the potential
efficacy, in 503 patients (stage ≥ II), of 3 cycles of
neoadjuvant triplet chemotherapy using cisplatin, 5-
fluorouracil and Epirubicin followed by surgery and
three cycles of adjuvant chemotherapy compared with
surgery alone for adenocarcinomas of the lower
œsophagus and stomach. The results are well known,
with a significant down staging in the chemotherapy
arm in terms of size of tumour (p < 0.001) and a
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(36% perioperative chemotherapy vs. 23% surgery alone,
p = 0.009). This perioperative treatment regimen remains
the standard of treatment in Europe. The FNCLCC AC-
CORD 07-FFCD 9703 trial [10] included 224 patients
with an adenocarcinoma of the lower œsophagus and
oesophago-gastric junction. Surgery alone was compared
to perioperative chemotherapy with cisplatin and 5-
fluorouracil, with results essentially confirming the find-
ings of the MAGIC trial. The R0 resection rates were
87% and 74% respectively (p = 0.04) and the overall sur-
vival rate at 5 years was 38% vs. 24%, respectively, (p =
0.021). Neither of these trials performed a sub-group
analysis for patients with a SRC. Further, preliminary
data has suggested the need for a specific treatment
strategy for SRCs because of a more advanced stage at
diagnosis, with a greater prevalence of lymph node inva-
sion and peritoneal carcinomatosis, a lower rate of R0
resection, earlier and more frequent disease recurrence
and finally a worse overall prognosis [12].
Recently Messager et al [8] have published the results
of a large multicentre comparative cohort study investi-
gating the impact of peri-operative chemotherapy on
survival in patients with SRC gastric tumours. It repre-
sents the largest study conducted on this histological
subtype and involved analysis of 1050 patients diagnosed
with SRC gastric tumours. No survival benefit was dem-
onstrated for patients with SRC histology receiving peri-
operative chemotherapy. Nor did neoadjuvant therapy
result in tumour down-staging, down-staging of nodal
disease, or decrease the disease recurrence. Indeed the
authors found some evidence that disease progression
during neoadjuvant treatment may have occurred in this
subgroup of patients - extended resections were more
commonly required and a longer median survival for pa-
tients treated with surgery alone prior to the incorporation
of peri-oerative chemotherapy into the French guidelines
for GA in 2006. This provides a clear imperative of the as-
sessment of an alternative treatment strategy.
As several studies [11-14] have suggested a relative
chemo resistance for SRC tumours and delay in defini-
tive surgery may favour tumour progression [8] we hy-
pothesise that a policy of primary surgery for SRC
tumours, followed by adjuvant chemotherapy, will im-
prove overall survival at 2 years when compared to a
standard peri-operative chemotherapeutic strategy. This
primary outcome criteria is justified as it provides a
short term evaluation criteria (important in view of the
very poor prognosis associated with this disease) and
survival at 24 months has been found in a multicentre
retrospective series of over 1000 patients to be signifi-
cantly different (27% vs. 10%) [8].
This randomised trial will provide high level evidence
regarding the value of a strategy of primary surgery forSRC gastric tumours. Whilst the development of new
biomarkers and associated targeted therapies are awaited
to individualise gastric cancer therapy, the results of this
trial should will help further in devising individualised
protocols of patient care in a tumour group whose diver-
sity increasingly demands assessment of alternative
strategies.
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